Carcinoid tumors.

Robin P. Boushey, Alan P B Dackiw

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Carcinoids are rare endocrine tumors that can develop in several organs in the body. Clinically, patients can have a wide spectrum of signs and symptoms that range from incidental findings of a polyp during endoscopy to the carcinoid syndrome characterized by severe flushing, diarrhea, abdominal cramping, and life-threatening right-sided heart failure. Most carcinoid tumors are indolent but can metastasize to regional lymph nodes and to other organs, including the liver, bone, and the central nervous system. Treatment is determined by tumor location and by the presence of distant metastasis. Surgical resection of the tumor is advocated in patients with localized disease and can often be curative. Long-acting somatostatin analogs, including octreotide, octreotide long-acting repeatable, and lanreotide prolonged release, are effective in providing symptom relief in patients with the carcinoid syndrome. Patients with metastatic disease to the liver that is refractory to somatostatin treatment should be considered for hepatic artery occlusion. Overall, 5- and 10-year survival rates in patients with metastatic disease are favorable, although tumors can be resistant to most forms of medical or surgical therapy.

Original languageEnglish (US)
Pages (from-to)319-326
Number of pages8
JournalCurrent Treatment Options in Oncology
Volume3
Issue number4
StatePublished - Aug 2002

Fingerprint

Carcinoid Tumor
Octreotide
Somatostatin
Neoplasms
Incidental Findings
Hepatic Artery
Polyps
Endoscopy
Signs and Symptoms
Liver Diseases
Diarrhea
Therapeutics
Survival Rate
Central Nervous System
Heart Failure
Lymph Nodes
Neoplasm Metastasis
Bone and Bones
Liver

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Carcinoid tumors. / Boushey, Robin P.; Dackiw, Alan P B.

In: Current Treatment Options in Oncology, Vol. 3, No. 4, 08.2002, p. 319-326.

Research output: Contribution to journalArticle

Boushey, RP & Dackiw, APB 2002, 'Carcinoid tumors.', Current Treatment Options in Oncology, vol. 3, no. 4, pp. 319-326.
Boushey, Robin P. ; Dackiw, Alan P B. / Carcinoid tumors. In: Current Treatment Options in Oncology. 2002 ; Vol. 3, No. 4. pp. 319-326.
@article{608467c222ff4f9aad5960d7f4c6e241,
title = "Carcinoid tumors.",
abstract = "Carcinoids are rare endocrine tumors that can develop in several organs in the body. Clinically, patients can have a wide spectrum of signs and symptoms that range from incidental findings of a polyp during endoscopy to the carcinoid syndrome characterized by severe flushing, diarrhea, abdominal cramping, and life-threatening right-sided heart failure. Most carcinoid tumors are indolent but can metastasize to regional lymph nodes and to other organs, including the liver, bone, and the central nervous system. Treatment is determined by tumor location and by the presence of distant metastasis. Surgical resection of the tumor is advocated in patients with localized disease and can often be curative. Long-acting somatostatin analogs, including octreotide, octreotide long-acting repeatable, and lanreotide prolonged release, are effective in providing symptom relief in patients with the carcinoid syndrome. Patients with metastatic disease to the liver that is refractory to somatostatin treatment should be considered for hepatic artery occlusion. Overall, 5- and 10-year survival rates in patients with metastatic disease are favorable, although tumors can be resistant to most forms of medical or surgical therapy.",
author = "Boushey, {Robin P.} and Dackiw, {Alan P B}",
year = "2002",
month = "8",
language = "English (US)",
volume = "3",
pages = "319--326",
journal = "Current Treatment Options in Oncology",
issn = "1527-2729",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Carcinoid tumors.

AU - Boushey, Robin P.

AU - Dackiw, Alan P B

PY - 2002/8

Y1 - 2002/8

N2 - Carcinoids are rare endocrine tumors that can develop in several organs in the body. Clinically, patients can have a wide spectrum of signs and symptoms that range from incidental findings of a polyp during endoscopy to the carcinoid syndrome characterized by severe flushing, diarrhea, abdominal cramping, and life-threatening right-sided heart failure. Most carcinoid tumors are indolent but can metastasize to regional lymph nodes and to other organs, including the liver, bone, and the central nervous system. Treatment is determined by tumor location and by the presence of distant metastasis. Surgical resection of the tumor is advocated in patients with localized disease and can often be curative. Long-acting somatostatin analogs, including octreotide, octreotide long-acting repeatable, and lanreotide prolonged release, are effective in providing symptom relief in patients with the carcinoid syndrome. Patients with metastatic disease to the liver that is refractory to somatostatin treatment should be considered for hepatic artery occlusion. Overall, 5- and 10-year survival rates in patients with metastatic disease are favorable, although tumors can be resistant to most forms of medical or surgical therapy.

AB - Carcinoids are rare endocrine tumors that can develop in several organs in the body. Clinically, patients can have a wide spectrum of signs and symptoms that range from incidental findings of a polyp during endoscopy to the carcinoid syndrome characterized by severe flushing, diarrhea, abdominal cramping, and life-threatening right-sided heart failure. Most carcinoid tumors are indolent but can metastasize to regional lymph nodes and to other organs, including the liver, bone, and the central nervous system. Treatment is determined by tumor location and by the presence of distant metastasis. Surgical resection of the tumor is advocated in patients with localized disease and can often be curative. Long-acting somatostatin analogs, including octreotide, octreotide long-acting repeatable, and lanreotide prolonged release, are effective in providing symptom relief in patients with the carcinoid syndrome. Patients with metastatic disease to the liver that is refractory to somatostatin treatment should be considered for hepatic artery occlusion. Overall, 5- and 10-year survival rates in patients with metastatic disease are favorable, although tumors can be resistant to most forms of medical or surgical therapy.

UR - http://www.scopus.com/inward/record.url?scp=0036673492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036673492&partnerID=8YFLogxK

M3 - Article

C2 - 12074768

AN - SCOPUS:0036673492

VL - 3

SP - 319

EP - 326

JO - Current Treatment Options in Oncology

JF - Current Treatment Options in Oncology

SN - 1527-2729

IS - 4

ER -